Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations study identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://hughk260hpx3.wikirecognition.com/user